Neutropenia

The investigational targeted radiotherapy iopofosine I 131 improved survival for certain patients with Waldenström’s macroglobulinemia, according to the agent’s manufacturer.

Jae Park, MD, compared the moment to a baby being born.

Individuals with relapsed or refractory lymphoma who received chimeric antigen receptor T-cell therapy experienced a wide range of adverse events compared with those who received other treatments, study results showed.

SAN DIEGO — Limited duration loncastuximab tesirine in addition to rituximab appeared well tolerated and highly effective for relapsed or refractory follicular lymphoma, according to data presented at ASH Annual Meeting and Exposition.

Healio spoke with David Andrew Sallman, MD, about unmet needs in myelodysplastic syndrome.

Healio spoke with David Andrew Sallman, MD, about complications in myelodysplastic syndrome.

Daily treatment with mavorixafor improved outcomes among patients with warts, hypogammaglobulinemia, infections and myelokathexis, or WHIM syndrome, in the 4WHIM phase 3 clinical trial, according to the drug’s developer, X4 Pharmaceuticals.

Use of different antibody-drug conjugates resulted in a variety of significant and in some cases serious treatment‐associated adverse events, according to results of a systematic review and meta-analysis published in Cancer.

Plinabulin demonstrated similar efficacy to pegfilgrastim for the prevention of chemotherapy-induced neutropenia, according to results of a randomized phase 3 study published in JAMA Network Open.

Most patients with acute myeloid leukemia who responded to treatment with venetoclax plus azacitidine in the VIALE-A study required dosing modifications to manage cytopenia, according to a presentation from ASH Annual Meeting and Exposition.